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ABSTRACT
Objective: A chronic wound fails to progress through the phases of wound healing in an orderly and appropriate process, and poses a major challenge 
to wound care professionals. Pressure ulcers (PUs) and diabetic foot ulcers (DFUs) are classified as chronic wounds. Antiseptics, such as povidone-
iodine (PVP-I), are often used to treat bacterial infections in chronic wounds; however, their efficacy and ability to accelerate wound healing has come 
into question. As a result, current medical research is now focusing on alternative and natural antiseptic agents, such as honey, for the treatment 
of chronic wounds. The aim of this study was to analyze the wound healing effects of honey in PU and DFU treatment in comparison to standard 
antiseptic care.
Methods: A systematic literature search of PubMed, ScienceDirect, and ClinicalKey was conducted to identify all published data of clinical trials and 
narrative reviews that investigated or reported the use of honey and standard antiseptics in the treatment of PUs and DFUs in adults. A keyword search 
was then performed using the following keywords: “PUs”, “DFUs”, “antiseptics”, “PVP-I”, “honey”, “Manuka honey (MH)”, and “wound healing”. Database 
restrictions were implemented based on the inclusion and exclusion criteria, notably the report’s availability, completion status and language, the 
sample populations’ age, as well as, the date of publication. A preferred reporting item for systematic review and meta-analysis (preferred reporting 
items for systematic reviews and meta-analyzes) diagram was constructed illustrating the study selection process. The eligibility of articles was 
assessed by the screening of titles, abstracts and full texts. A total of 12 articles were included in this study comprising of 775 patients with PUs, DFUs 
or a combination of PUs and DFUs.
Results: Results indicated that honey reduced bacterial infection, reduced pain and edema experienced by patients, reduced the odor of the wound 
and promoted wound healing in the treatment of chronic ulcers. Honey was also found to be effective in the process of debridement and exudate 
removal.
Conclusion: Honey was found to be highly effective in the treatment of PUs and DFUs and should be considered as an alternative to standard antiseptic 
care in the treatment of chronic wounds. However, the literature in this study is limited and so further research into honey and its antiseptic-promoting 
activity in wound healing is recommended.
Keywords: Pressure ulcers, Diabetic foot ulcers, Antiseptics, Povidone-iodine, Honey, Wound healing.
INTRODUCTION
Normal wound healing consists of four stages: hemostasis, 
inflammation, proliferation, and remodeling. Chronic wounds 
develop and are slow to heal as a result of an interruption in the 
normal healing process [1,2]. Chronic wounds do not progress past 
the inflammatory phase and are characterized by heat, redness, pain, 
and swelling [1] and are associated with long hospital stays and 
high medical costs [2]. The frequency of patients living with chronic 
wounds is relatively high globally, with an average of 120 per 100,000 
people [2]. The prevalence of chronic wounds increases with age and 
are frequently found in older people [2]. Pressure ulcers (PUs) and 
diabetic foot ulcers (DFUs) are classified as chronic wounds and place 
a high burden on health care systems. This review will focus on the 
treatment of these wounds as they share comparable pathogeneses 
that is a combination of decreased angiogenic response and increased 
pressure [3].
Hospital-acquired PUs are localized areas of damage to the skin and 
soft, underlying tissue over bony prominences and develop due to 
pressure and reduced blood circulation [1]. These injuries occur in 
3–34% of hospitalized patients globally and often affect patients who 
are immobile, bedridden, suffer from cognitive impairment or have 
underlying comorbidities [1,3].
DFUs are open wounds that develop in patients with diabetes mellitus 
(DM) [4-6] due to damaged capillaries, hyperglycemia, nerve damage 
and a compromised immune system resulting in small, benign wounds 
that become infected [5]. The global DFU prevalence is 6.3%, of which 
a third may result in amputation [4]. DFUs develop on the plantar 
aspect of the foot causing permanent nerve damage and may result in 
amputation of the lower limb [6].
PUs and DFUs impede blood flow, reduce nutrient supply, and deprive 
tissues of oxygen resulting in the accumulation of toxic waste products 
and the development of localized ischemia, tissue inflammation and 
shearing [7]. Chronic wounds pose a major challenge to wound care 
professionals as the treatment process is complex, time-consuming and 
costly [7,8]. Morbidity is high in patients with these types of wounds 
and the cost associated with chronic wound treatment highlights the 
necessity to branch into alternative wound treatment options.
This review aims to analyze the efficacy of honey as an alternative 
to standard antiseptic care, such as povidone-iodine (PVP-I), in the 
treatment of Pus and DFUs. Complete wound healing can be achieved 
if they are detected early and if the appropriate treatment method 
is applied [2,8]. If these wounds are not treated properly, they may 
become fatal [2]. Various intrinsic and extrinsic factors contribute 
to the development and pathogenesis of these chronic wounds and 
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need to be identified before any treatment can be considered [2] 





Intrinsic, predisposing (patient-related) factors influence the 
supporting structures of the skin and the lymphatic system [9]. These 
factors severely affect the ability of soft tissue and skin to withstand 
uninterrupted external forces [9]. Maintaining good nutrition and 
hydration supports blood flow to wounded tissue and prevents 
fragile skin breakdown [10]. Patients suffering from nutritional 
deficiencies, such as malnutrition or anemia, are more susceptible 
to PU formation [11]. Hence, it is recommended that patients follow 
a high-protein, vitamin C-, iron- and zinc-rich diet [11]. These 
recommendations may vary and are carefully adjusted according to 
the presence of any underlying comorbidities and the patient’s health 
status [10,12]. Sufficient oxygen supply is required for all stages of 
wound healing, which implies that patients with cardiac disease, 
diabetes or patients with hypercholesterolemia are more susceptible to 
PU formation as their oxygen levels may be compromised [12]. Spinal 
cord injuries, arthropathies, or progressive neurological disorders 
(Parkinson disease, sclerosis and Alzheimer disease) are conditions 
that increase the patient’s risk to primary external factors such as 
paralysis and/or loss of feeling and may result in PU formation [10,12]. 
The patients who suffer from neurological diseases (depression or 
psychosis) are more susceptible to PU development as a result of 
poor diet, secondary physical health conditions (i.e., diabetes) or the 
tendency to neglect personal hygiene (incontinence), thus making the 
skin more vulnerable to infection and maceration [10,11,12].
Extrinsic risk factors
Extrinsic factors include direct pressure, friction and shear force [8]. 
These forces compress soft tissues against bony prominences and slow 
down capillary blood flow to local tissue [8]. They shear and tear blood 
vessels to the point where oxygen supply to the tissue is halted [13]. 
Moisture is another extrinsic risk factor that alters the resistance of 
the epidermis by reducing its tensile force, softening the surface of 
the skin and altering the cutaneous chemical environment, which 
makes the skin susceptible to maceration by external forces, injury and 
ulceration [8]. Once these factors have been identified, interventions to 
prevent the development of PUs can be applied.
DFUs
There are several common risk factors amongst diabetic patients 
that contribute to the development of DFUs [14]. The two largest 
contributing factors for DFU development are peripheral neuropathy 
and peripheral vascular disease (PVD) [14]. Peripheral neuropathy 
involves damage to nerve endings in lower limbs owing to the high 
blood glucose levels and is common in diabetic patients [14]. The 
patients experience disconnections from normal sensations, such as 
numbness, pain, or altered vibrations. Neuropathy in the peripheral 
limbs increases the risk for the development of lesions which may 
progress to ulcers owing to the lack of feeling in these regions [14]. PVD 
is a circulatory disorder that reduces blood flow and constricts blood 
vessels (the aortoiliac segment and the superficial femoral artery) in 
the lower extremities [14]. PVD slows down the rate of healing and is a 
major risk factor for lower-limb amputation [14]. DFUs are open wounds 
that have a high risk for infection [14,15] which may become systemic 
and enter the bloodstream and bone which can result in amputation 
and death [14,15]. Obesity, hypertension, smoking, insulin usage, poor 
glucose control or poor footwear that causes skin breakdown, are 
some of the lifestyle risk factors that contribute to the development 
of DFUs [14]. Arterial insufficiency, limited joint mobility (Charcot 
joint) and previous foot ulcerations or lower extremity amputations 
are additional contributing factors that result in DFU formation and 
impaired wound healing [14].
INTERVENTIONS
Interventions preventing the development of PUs
Several scales and scoring methods have been developed to quantify 
a person’s risk of PU development by identifying the presence of risk 
factors. The Braden-, Norton-, and the Waterlow scale are three of the 
most widely used tools for risk assessment [10,11]. In combination 
with these tools, regular skin assessments are vital. Hospital-acquired 
PUs are common in the patients who are limited in their movement, 
especially geriatrics [12]. The promotion of movement, repositioning 
methods and alternate support surfaces, such as sheepskin, are used 
in combination with wound management strategies to reduce external 
pressures on the affected area [11,13]. The use of skin moisturisers 
and prophylactic foam dressings are also advised [11-13]. Nutritional 
deficiencies should be identified and rectified as malnutrition may 
contribute to PU development [13]. Paralyzed patients in wheelchairs are 
encouraged to shift their weight often and to sit on foam or gel cushions 
to reduce pressure [13]. The correct management of incontinence is 
essential, as urine or fecal matter contain acids and enzymes which may 
cause skin excoriation [13]. Incontinence in combination with limited 
mobility increases the risk for the development of PUs [13].
Interventions preventing the development of DFUs
Prevention assessments and techniques are essential to prevent 
the development of DFUs and avoid possible amputation [15,16]. 
Daily inspections, instructions on foot hygiene and wearing proper 
footwear are a few interventions that the patient can carry out 
themselves [15]. The patients who are at high risk for foot ulcers are 
provided with therapeutic shoes with pressure-relieving insoles [15]. 
Nutritional deficiencies delay the wound healing process and 
healthcare professionals need to ensure that patients meet the dietary 
requirements to ensure successful healing during treatment [15]. 
Obesity is a risk factor for DFU development as it increases stress on 
the feet and reduces blood flow, therefore maintaining a healthy weight 
is important to prevent blood occlusions, blisters and cuts [14,15]. 
Tobacco products have been linked to circulatory problems and 
contain chemicals that may slow down healing [14], thus cessation of 
smoking is recommended [14]. Daily blood-glucose level monitoring 
in the patients with diabetes is essential as high glucose levels may 
lead to further foot complications and difficulty in healing [15,16]. 
Medical professionals and primary caregivers need to carry out regular 
foot-care examinations to detect any developing lesions or sores 
regularly [14- 16].
The development and manifestation of PUs and DFUs is complex and 
multifactorial [8,9]. In many cases, preventative interventions are not 
applied in time to prevent the formation of a chronic ulcer and a patient 
may present with an ulcer that is progressive [8,9,14,16]. It is therefore 
of utmost importance to promptly determine the stage of the PU or DFU 
to start the appropriate treatment that will aid in wound healing.
CLASSIFICATIONS OF ULCERS
Stages of PUs
The National PUs Advisory Panel categorized PUs into different stages 
(Table 1). Originally, there were four (I-IV) stages however, two new 
categories were recently introduced namely, deep tissue injury and 
unstageable PUs [9]. The stages of the PUs are grouped by the severity of 
symptoms, depth of the damage and the presentation of the wound [9]. 
To determine the stage of the PU; slough, exudate and eschar should be 
removed to expose the base of the wound [9].
PUs are wounds that develop in the upper layers of the skin owing to 
sustained pressure, that eventually extends outward and downward 
into the deeper tissue layers [1,3]. Higher graded ulcers present the 
greatest risk of infection [1,3]. Stage II-IV PUs are often characterized 
by an inflammatory reaction as well as systemic infection or local 
bacterial colonization [1,3,11]. If not treated correctly or early enough 
the wound can become severely infected and may require additional 
systemic antibiotics [3,11]. Stage III and IV PUs present with slough 
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and exudate that may require additional debridement techniques to 
correctly treat the wound and prevent infection [1,3,11]. ‘Suspected 
deep tissue injury’ and ‘Unstageable PU’, were introduced to assist with 
documentation and classification of the wound [11]. PUs in either of 
these two categories must be treated immediately with preventative 
therapeutic measures [11].
Grading of DFUs
The classification of DFUs can provide a reasoned approach to 
treatment options and can assist in predicting the outcome thereof [15]. 
There are several classification systems regarding DFUs; however, the 
Wager ulcer classification system is most widely used (Table 2) [15]. 
This system classifies DFUs from grades 0–5 based on the depth of the 
wound; the presence of gangrene or osteomyelitis and the severity 
of tissue necrosis [15]. It, unfortunately, does not make provision for 
ischemia and infection which may be present [15].
DFUs must be detected early enough to prevent the development of a 
severe injury that may result in amputation [4,5,15]. Grade 0 DFUs are 
the least severe and can be treated accordingly if they are detected early. 
However, most patients present with Grade 1 or 2 DFUs as patients only 
recognize the development of a serious injury once the subcutaneous 
tissue is exposed [15]. This supports the need for patients, who are 
diabetic and susceptible to DFU formation, to complete regular foot 
examinations and monitor their blood sugar levels carefully as failure 
to do so, will increase the risk of ulcer formation. Grade 4 and 5 DFUs 
are the most severe and present with extensive damage. Gangrene and 
necrotic tissue are present in these wounds which increases bacterial 
growth and infection. If left untreated or if the incorrect treatment 
method is applied to these wounds, amputation will be required.
TREATMENT OF ULCERS
Treatment of PUs
The treatment of PUs is challenging as these wounds can become chronic 
and give rise to several complications such as sepsis, abscesses, joint and 
bone infections and cellulitis [7,17]. There are several treatment options 
available to manage PUs and avoid secondary conditions [17]. Surgical 
debridement is sometimes necessary to remove necrotic tissue [7]. Topical 
or systemic, antibiotics and antiseptics may be administered to treat 
infected PUs and reduce microbial colonization [17]. Infection is a major 
challenge in PU treatment and may cause bacteremia and septicemia [7].
Treatment of DFUs
DFUs treatment focuses on offloading, debridement and wound 
closure without infection [18]. The relief of pressure and elevation of 
the infected foot are essential components during treatment [15,18]. 
Offloading includes patients using wheelchairs or crutches to 
completely prevent pressure exerted on the affected foot [18]. Total 
contact casts [18] are used to reduce pressure and its application has 
shown to be successful. Physicians, clinicians, and wound specialists 
often use different debridement techniques to remove any dead skin, 
foreign bodies or callus within the wound as these may contribute 
to infection and malodor of the wound [14,15,18]. Debridement also 
reduces the pressure exerted on the wound that may contribute to 
impeding wound closure and healing [15,18]. If the ulcer is not correctly 
debrided, it may increase the risk of amputation of the lower limb [18]. 
Wound dressings are necessary to absorb excess fluid, prevent tissue 
desiccation, and protect the wound from contamination [15,18]. The 
management and successful treatment of an ulcer are determined by its 
severity and presence of infection [15]. Often, DFUs are polymicrobial, 
which necessitates the use of antimicrobial and antiseptic impregnated 
wound dressings [15,18]. Osteomyelitis, cellulitis and localized 
infections are common in DFU affected patients; therefore, the correct 
antiseptic must be applied to the wound [15,18].
Antiseptics are commonly used in PU and DFU treatment to inhibit the 
growth and development of bacteria and assist in wound healing [7]. 
Different types of antiseptics are available and vary in cost, effectiveness, 
use and side effects [7]. Drug and antiseptic-resistant bacteria pose an 
increased challenge in the successful treatment of PUs and DFUs, which 
accentuates the need for effective antiseptics to be selected to ensure 
that successful wound healing can be achieved.
ANTISEPTICS
Antiseptics are broad-spectrum agents that are effective against Gram-
positive and Gram-negative bacteria [7,19]. The ideal antiseptic should 
have several characteristics namely, (i) it must be active against viruses, 
fungi and spores; (ii) be bactericidal and not just bacteriostatic; (iii) 
have an accumulative effect and act rapidly; (iv) not exert irritation and 
toxic effects in the wound bed; (v) be soluble in water; (vi) persist over 
time and not become susceptible to contamination; (vii) be successful 
in the drying, debriding and cleansing of wounds; and (viii) be cost-
effective [7,19]. Different antiseptic-impregnated wound dressings are 
used, such as chlorhexidine, pyodine, silver sulfadiazine, cadexomer 
iodine, and PVP-I [19]. The choice of the type of antiseptic used will 
depend on the grading or staging of the ulcer and the secondary 
conditions that the patient may present with.
PVP-I
PVP-I, also known as pyodine or iodopovidone, is a commonly used 
antiseptic for the treatment of burns, infected wounds, PUs and 
Table 2: Grading of DFUs according to the Wagner ulcer 
classification system
Grade Description
Grade 0 Intact skin in patients who are at high risk [15].
Grade 1 Ulcers are superficial with exposed subcutaneous 
tissue [15].
Grade 2 Ulcers extend to the ligament, tendon or fascia without 
abscess formation or osteomyelitis [15].
Grade 3 Ulcer extends to the deep tissue and present with 
osteomyelitis and abscesses [15].
Grade 4 Ulcers present with localized gangrene on patched parts of 
the forefoot or the heel [15].
Grade 5 Ulcers are the most severe and extensive as they present 
with extensive gangrene in the whole foot [15]. 
Table 1: Stages of PUs according to NPUAP
Stage Description
Stage I Non-blanchable erythema of intact skin, 
indicating an interruption in blood flow to the 
skin [11]. The skin appears redder, warmer and 
firmer than usual. The color change may indicate 
the beginning of a serious injury to the deep 
tissue [11].
Stage II Partial-thickness loss of the epidermis, dermis 
or both [11,12]. The ulcer presents as a shallow, 
pus-filled, open wound with a red/pink wound 
bed [11,12].
Stage III The ulcer develops underneath the skin 
and presents as a crater with slough and 
exudate [11,12].
Stage IV This is the most severe stage of ulcer 
development. The dermis is severely damaged 
and recedes into the muscle and bone. The 




Injuries that develop deep below discolored 
skin [11]. A blood-filled blister may develop [11].
Unstageable PU The bottom of the wound bed is covered in slough 
and eschar [11]. There is extensive tissue damage 
with full-thickness tissue loss [11]. The stage 
of the wound can only be determined once the 
wound has been debrided [11]. 
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DFUs [20]. It is a broad-spectrum, water-soluble polymer comprised of 
povidone, hydrogen iodide and iodine [21]. PVP-I’s antimicrobial action 
occurs after iodine segregates from the polymer complex [20,21]. Once 
in the free form, iodine rapidly penetrates microbial cell membranes 
and interacts with nucleotides, proteins, and fatty acids which 
ultimately results in rapid cell death [20,21]. PVP-I might cause several 
adverse effects such as irritation, staining and swelling of the skin, 
and edematous erythema [21]. It is contraindicated in patients with 
thyroid-related diseases (i.e., hyperthyroidism), renal impairment or 
pregnant women [21]. Many researchers believe that PVP-I may have a 
deleterious effect on healing tissue due to the strong bactericidal effects 
of its iodine preparation [21]. This antiseptic also requires secondary 
dressings, such as hydrocolloids or hydrogels, for it to be effective in the 
treatment of infected PUs and DFUs [20]. PVP-I is the main antiseptic of 
interest in this study as its efficacy in the treatment of ulcers has been 
studied and noted in several clinical trials and reviews.
The healing process of PUs and DFUs is complicated by the widespread 
development of antimicrobial and antiseptic-resistant bacterial 
infections, causing antiseptic treatment to become less effective [19]. 
The use of certain antiseptics, such as PVP-I, do not necessarily meet 
the requirements to eradicate bacterial infections [19], which opens the 
possibility for the use of alternative and more natural antiseptic agents, 
such as honey, for the treatment of PUs and DFUs. The composition 
of honey and its physical and chemical properties which give rise 
to its ability to counter microorganisms located in the wound bed of 
infected PUs and DFUs in comparison to conventional antiseptics, have 
been thoroughly studied [19]. Promising results have been obtained 
regarding the antiseptic and antimicrobial activity of honey [19] and 
can also be used in combination with antibiotics or wound dressings 
to further enhance its activity. It has been approved as a therapeutic 
alternative for treatment against antibiotic-resistant bacteria based on 
its in vitro and in vivo efficacy [19]. This review will focus on honey’s 
antiseptic efficacy, its use in the treatment of infected PUs and DFUs 
and its molecular and physical properties that give rise to its ability to 
promote wound healing in the treatment of PUs and DFUs.
HONEY
Scientists have been exploring the various bioactivities of honey 
which may cohesively expedite the healing process of chronic wounds 
more effectively in comparison to current therapeutics. Honey is a 
supersaturated sugar solution composed of 180 different compounds 
which contribute to its effectiveness [22]. The main components of honey 
include various sugars, water, and proteins [22,23]. Flavonoids and 
phenolic acids within honey are believed to determine its antimicrobial 
and antioxidant activities [23]. Several other factors have been found 
to contribute to the antimicrobial activity of honey, such as its low 
water content and high sugar concentration, which aids in providing 
a protective barrier to prevent infection [22,23]. Honey’s mild acidity 
and hydrogen peroxide (H2O2) content provide additional antimicrobial 
effects that aid in bacterial decolonization in wounds [23]. Different types 
of honey are available and their compositions may differ depending on 
where they were harvested as well as whether they have undergone 
chemical sterilization or not. Natural and floral honeys have been 
widely studied and applied to wounds; however, raw honey’s high sugar 
content makes it susceptible to crystallization [22]. Water is released 
during the process of crystallization which allows yeast and bacteria 
to initiate fermentation within the honey [22]. In addition, at elevated 
temperatures, the peroxide activity in honey can be destroyed and its 
antimicrobial effects can be limited [22,23]. However, honey derived from 
the Leptospermum tree retains its antimicrobial activity in the presence 
of such high temperatures and are known as non-peroxide honey [22,23]. 
MH is a medical-grade, Leptospermum derived honey [22,23] which has 
been shown to have lesser side effects, and it can be used in the majority 
of patients undergoing PU and DFU treatment.
MH
MH is a mono-floral honey that is exclusively derived from the 
Leptospermum scoparium tree in New Zealand [24]. MH contains 
Chemical properties of honey
The chemical properties of honey namely, its low pH (3.2–4.5) [23] 
and low H2O2 content, makes it an effective antibacterial and 
antimicrobial agent that can assist in wound healing [22,23]. Honey 
is also able to activate inflammatory cells, such as neutrophils, which 
aids in the removal of bacteria and damaged tissue indicating that it 
has effective debridement abilities [23]. Through the use of autolytic 
debridement, honey uses its strong osmotic power to move lymphatic 
fluid from subcutaneous tissue into scar tissue. As a result, damaged 
and necrotic tissue is removed [23]. Neutrophils also assist in collagen 
and elastase deposition which promote wound healing and tissue 
regeneration [22,23]. Honey upregulates vascular homeostasis and 
angiogenesis within the wound, which provides blood, nutrients and 
oxygen to proliferating cells involved in tissue formation [22,23]. As a 
result, honey is effective in reducing wound size and improving the rate 
of novel tissue deposition. Honey is also known to aid in pain relief and 
was shown to exhibit anti-odor effects [22,23]. The mechanisms behind 
honey’s antibacterial, anti-inflammatory, antioxidant debridement, 
pain-relief, and epithelialization-promoting effects will be analyzed 
further in this review [22].
MATERIALS AND METHODS
Search strategy for data sources
A systematic literature search was performed using ClinicalKey, 
Cochrane Library, Clinicaltrials.gov, PubMed, MEDLINE, and Science 
Direct. A keyword search was then performed using the following 
keywords: “PUs”, “DFUs”, “antiseptics”, “PVP-I”, “honey”, “MH”, and 
“wound healing”. Boolean operators, “AND” and “OR” were used to 
make each search more precise and provide information that was most 
relevant to compile this review.
Screening and data extraction
Articles were screened according to the inclusion and exclusion criteria. 
All the studies relating to honey in the treatment of PUs and DFUs were 
included in the present review. The resulting and filtered articles were 
assessed using preferred reporting items for systematic reviews and 
meta-analyzes (PRISMA) diagram by removing articles that did not 
fall within the inclusion and exclusion criteria. In addition, duplicated 
articles were also removed by screening titles and abstracts. The 
abstracts of the remaining articles were further analyzed to identify 
whether they were relevant to be included in the study.
The inclusion of studies was determined by the author and corroborated 
by the co-authors based on eligibility criteria. To be included, studies 
had to be free full-text studies assessing the use of honey in the 
treatment of PUs and DFUs in adults. The study had to report on ages, 
the etiology of the ulcer, period of the study, and the application of both 
an antiseptic and honey.
Inclusion criteria
Only articles published in English were included in this study. Articles 
published between 2000 and 2021 were eligible and in vivo articles 
that included preclinical trials were also considered. Phase I- IV clinical 
trials in adults and articles that included clinical trials that occurred 
for longer than two (2) months were also included. Articles that were 
methylglyoxal which acts as an additional antimicrobial agent 
as it destroys bacterial flagella thus limiting the organism’s ability to
 move  and  adhere  to  surfaces  [25].  It  also  exerts  non-peroxide 
antimicrobial activity (NPA) [19,25]. NPA is the measure of MH’s 
ability to inhibit microbial growth [19,25]. Its NPA is measured
 and  graded  by  the  Unique  Manuka  Factor  (UMF)  [19].  The 
higher the UMF grading, the higher the antiseptic properties within 
the honey [19]. MH has shown promising in vivo activity in PU and DFU 
treatment  owing  to  its  chemical  properties  [19,25].  MH  is  also 
well-known  for  its  ability  to  lower  the  pH  of  a  wound,  clear  wound 
exudate,  maintain  hydration  and  inflammation  of  the  wound  bed, 
accelerate wound healing and reduce the size of the wound [19,21,25].
 Based  on  its  wound-healing  properties,  honey  may  be  an  effective 
therapeutic agent in the treatment of PUs and DFUs.
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published in accredited and peer-reviewed journals and systematic and 
meta-analyzes reviews were used for this study.
Exclusion criteria
Articles not published in English and before 2000 were excluded. 
Articles with patients younger than eighteen (18) years of age were 
excluded due to ethical reasons. Articles that included preclinical 
clinical trials or clinical trials that did not occur for longer than two 
(2) months and included <10 (10) patients were excluded. Case report 
studies were also excluded.
A PRISMA diagram was constructed illustrating the study selection 
process (Fig. 1). The types of interventions used in the various studies 
were recorded. The duration of medical treatment, number of patients, 
and number of ulcers were retrieved from each study. The percentage 
of successful PU and DFU ulcer healing was recorded. The age of the 
patients was included to determine if they met the inclusion and 
exclusion criteria. The wound size and appearance of the wound were 
recorded before and after treatment to determine any positive outcomes.
A total of 3145 articles were retrieved of which 64 articles were 
eligible for inclusion after full-text screening. These articles provided 
qualitative and quantitative data, specifically on the framework of the 
efficacy of honey in the treatment of PUs and DFUs with antiseptics. 
Within the remaining articles, 12 articles provided quantitative and 
qualitative data, specifically addressing the comparison of honey and 
antiseptics in the treatment of PUs and DFUs. Relevant findings and 
associated statistical significance were extracted and summarized 
(Table 3). No statistical analysis was performed.
RESULTS
PUs and DFUs
In a randomized controlled trial (RCT) conducted by Gulati et al. (2014), 
the healing of chronic wounds with honey dressings in comparison to 
PVP-I dressings in adults was analyzed (Table 3) [21]. The trial was 
conducted over 6 weeks on adult patients. The majority of the PUs or 
DFUs had developed on the leg or ankle of the patients. The patients 
were randomized into two groups that is the honey group (n=23) and 
the PVP-I group (n=22). After the 6-week follow-up period, 3 patients 
were excluded as 2 patients developed adverse effects to the PVP-I 
treatment and one patient failed to follow-up [21]. In the honey group, 
31.82 % of the patients achieved complete wound healing at the end 
of the 6 weeks whereas none (0%) of the patients receiving PVP-I 
treatment attained complete wound healing [21]. The surface area 
and depth of ulcers increased with time thus treatment should aim 
to reduce the size and circumference of the wound [21]. The median 
surface area of the chronic wounds was recorded at the beginning and 
the end of the 6-weeks of treatment [21]. At week 0, the PVP-I group 
presented with a 4.25 cm2 median surface area wound which reduced 
to 1.95 cm2 at the end of week 6 [21]. In the honey group, the median 
surface area was 4.35 cm2, which reduced to 0.55 cm2 at the end of 
week 6 [21]. Gulati et al. (2014) concluded that honey dressings were 
more effective when compared to PVP-I in achieving complete healing; 
reducing wound surface area and pain, which increased the quality of 
life in the subjects with chronic wounds [21].
Zeleníková et al. (2019) [26] conducted a prospective interventional 
study aimed at determining the clinical effectiveness of honey dressings 
in the management of chronic wounds, mainly PUs and DFUs, in elderly 
persons receiving home care (Table 3) [26]. The sample comprised 
of forty (n=40) patients. The patients were randomly designated into 
two groups, one receiving honey treatment and the other receiving 
conventional treatment, including PVP-I. PUs in patients were graded 
as stage II, III or IV [26]. At the end of the 90-day observational period, 
a difference in the mean wound size between groups was found to be 
significant [26]. The mean size of wounds was smaller in subjects with 
honey dressings in comparison to the controls (conventional dressings 
[CD]). In the honey-treated group, the mean wound size decreased 
from 15.7 cm3 to 6.0 cm3, whereas the wound size in the control group 
decreased from 16.9 cm3 to 9.8 cm3. The patients receiving conventional 
(PVP-I) dressings reported a higher pain intensity level compared to the 
experimental group throughout the study [26]. Wound odor was also 
assessed during this study, and it was found that the odor was absent 
in 75% of the wounds in the experimental group receiving the honey 
treatment at the end of the study in comparison to 10% of wounds in 
the control group treated with PVP-I [26].
PUs
A cross-sectional study by Khadanga et al. (2014) was conducted to 
compare the effectiveness of honey and PVP-I in wound healing in 
decubitus ulcers [27]. The study consisted of forty (n=40) patients that 
presented with PUs over 10 days (Table 3). Twenty patients (n=20) 
(Group A) were treated with honey dressings whereas the other 
20 patients (Group B) received treatment using PVP-I dressings [27]. 
The mean wound size of each group was measured and recorded on 
day 1 and again on day 10. Group A exhibited a reduction in wound 
size from 32990.80±13284.29 cm3 to 2592.90±1276.05 cm3. Group B 
showed a reduction in wound size from 33840±12904.28 cm3 to 
29431±1660.14 cm3 [27]. Though the size of the wound decreased with 
the use of the honey dressing, it was not considered as significant in the 
study. Group A and B both exhibited a reduced bacterial load within the 
wound bed [27].
Fig. 1: Preferred reporting items for systematic reviews and meta-analyzes flow diagram
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Table 3: Overview of primary studies in PU and DFU treatment
Author (s) Title of study Design of study Wound etiology No. of 
patients
Type of intervention Outcome




to Compare the 
Effectiveness of 
Honey Dressing vs. 
Povidone Iodine 






PUs and DFUs 
included
n=45 Sterilized 
honey (n = 23) vs.
PVP-I group (n = 22)
- Faster wound healing 
was observed in wounds 
dressed with honey in 
comparison to PVP-I
- Honey was found to 
reduce pain and increase 
patient comfort












honey (MH) (n = 20) 
vs. Conventional 
dressings with 
PVP-I (CD) (n = 20)
- Honey accelerated 
wound healing
- Honey was superior in 
the reduction of wound 
size and caused less pain
- Honey was found to 
reduce the malodor of 
chronic wounds better 
than wounds treated 
with PVP-I
Khadanga et al. 
(2014) [27]
Effects of Topical 




PUs n=40 Honey group 
A (n = 20) vs.
PVP-I group B (n = 20)
- Honey was found to 
be more effective in 
the contraction of the 
wound surface although 
it was not considered as 
significant
Choudhary et al. 
(2015) [28]
Comparative study of 
honey and betadine 
in chronic ulcer 
healing
RCT Varied etiology-
PUs (n = 9) and 
DFUs (n = 9) 
included
n=30 Honey group 
A (n = 15) vs.
PVP-I group B
(n = 15)
- Honey was reported to 
be superior in terms of 
wound healing rate
- Honey was more 
effective in exudate 




A comparative study 
between honey and 
Povidone-iodine as 
dressing solution 
for Wagner type II 
diabetic foot ulcers
RCT DFUs n=30 Pure honey vs.
PVP-I (10%)
- Honey reduced oedema 
and odor. 
- Honey dressing 
changes were less 
painful.
- Wounds treated with 












n=63 MH (n = 32) vs.
CD (n = 31)
- Bacterial colonization 
decreased in the 
honey-treated group
- Honey was 
recommended as a 
cost-effective alternative 
as it reduces the length 
of hospital stay
Agarwal 
et al. (2015) [31]
A control 
clinical trial of 
honey-impregnated 
and Povidone-iodine 
dressings in the 
treatment of diabetic 
foot ulcers among 
Northern Indian 
subjects
RCT DFU’s n=36 Honey group A vs.
PVP-I group B
- Honey was able to 
reduce bacterial load 
and infection in the 
wound
- Honey treatment 
caused less pain 
experienced by the 
patients
- Honey reduced 
oedema of the wound 
and reduced discharge 
released
(Contd...)
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The role of honey in 
the management of 
diabetic foot ulcers
RCT DFUs n=200 Honey group 
A (n = 100) vs.
PVP-I/Hydrogen 
peroxide group 
B (n = 100)
- Honey was faster in 
eradicating infection
- Honey reduces the 
length of hospital stay
- Honey dressings 
provided faster wound 




A Pilot Randomized, 
Controlled Study of
Nanocrystalline 
Silver, Manuka Honey, 
and Conventional 
Dressing in Healing 
Diabetic Foot Ulcer
RCT DFUs n=31 MH (n = 10) vs.
Nanocrystalline 
silver (NAg) (n = 11) 
and
CD (n = 10)
- NAg is potentially 
better than MH and CD 
in DFU treatment
- MH is an effective 
and safe alternative 
antiseptic for DFU 
treatments
- MH- and nAg-treated 
groups exhibited a 
significant decrease 
in the microbial 
colonization of the 
wound
- Patients treated with 
MH dressings exhibited 
fewer adverse effects in 
comparison to NAg or 
CD treatment





dressing with honey 
dressing for the 




DFUs n=100 Honey group (n = 50) 
vs.
Pyodine (n = 50)
- A faster recovery time 
was observed in wounds 
treated with honey in 
comparison to pyodine 
group
- Honey dressing 
provided faster wound 
healing than the pyodine 
dressing and reduced 
the amputation rate
Ur-Rehman et al. 
(2013) [35]
Comparison 





Wagner’s grade s I & 
II diabetic foot ulcers
RCT DFUs n=60 Honey group (n = 50) 
vs.
PVP-I/saline 
group (n = 50)
- Honey dressings 
were more effective in 
reducing wound size 
in comparison to the 
PVP-I/saline dressing
Mukherjee et al. 
(2018) [36]
A Comparative Study 
of Effectiveness 
of Honey and 
Povidone-iodine in 




PUs and DFUs n=100 Honey group 
A (n = 50) (50% PUs 
and DFUs)
PVP-I group 
B (n = 50) (52% PUs 
and DFUs)
- Honey dressings 
reduced the degree of 
pain experienced by 
patients in comparison 
to PVP-I dressings
- Honey dressings 
accelerated wound 
healing
- Honey treatment 
provided better patient 
comfort in comparison 
to PVP-I treatment
Table 3: (Continued).
A prospective, randomized trial by Choudhary et al. (2015) aimed 
to compare the healing of various chronic ulcers, including PUs and 
DFUs, with the application of honey and betadine (PVP-I) dressings 
(Table 3) [28]. The study focused on analysing the efficacy of honey in 
wound healing. The study comprised of thirty patients (n=30) [28] that 
were divided equally into two groups: Group A that received the honey 
dressing and Group B that received the betadine dressing. The trial was 
conducted over a period of 1 year. Of the 30 patients, 9 patients presented 
with PUs and 9 presented with DFUs, with 4 allocated to Group A and 
5 to Group B, respectively. At the time of admission, the mean wound 
score for the patients with PUs in Group A was 14.5±3.3 cm2 and after 
2-weeks of treatment, the wound score had reduced to 6±5.3 cm2 [28]. 
In comparison, the admission score for Group B was 14.4±2.6 cm2 and 
6±3.8 cm2, respectively. The mean wound score for the patients with 
Author (s) Title of study Design of study Wound etiology No. of 
patients
Type of intervention Outcome
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DFUs in Group A at the time of admission was 15.8±4.1 cm2 and after 
2-weeks of treatment, the wound score had reduced to 7.4±2.7 cm2 [28]. 
In comparison, the admission score for Group B was 15.7±2.0 cm2 and 
10.25±4.0 cm2, respectively. In all patients treated with honey, 80% of 
patients exhibited improved wound healing whereas 60% of patients 
treated with betadine exhibited improved wound healing [28].
DFUs
Shukrimi et al. (2008) conducted a randomized clinical trial to compare 
the effect of non-sterile, pure honey with PVP-I in 30 patients with 
DFUs (Table 3) [29]. The study was divided into two study arms; a 
honey dressing group and a PVP-I dressing group. The patients were 
divided equally between the two groups and physicians carefully 
monitored the blood glucose levels of these patients [29]. The study 
focused on analyzing the eradication of bacterial organisms such 
as Staphylococcus species (sp)., Streptococcus sp., Pseudomonas sp., 
Bacteroides, Enterococcus, and Acinetobacter sp., and Escherichia coli, 
present in the ulcers [29]. The study concluded that wounds infected 
with Staphylococcus sp. and Streptococcus sp. treated with honey, 
exhibited reduced bacterial colonization [29]. However, ulcers infected 
with Bacteroides and Enterococcus did not show a reduction in bacterial 
load. The honey treated group also showed a reduced mean wound 
healing time of 14.4 days in comparison to the PVP-I group, which 
required 15.4 days [29].
A study conducted by Kamaratos et al. (2014) analyzed the wound-
healing effects of MH-impregnated dressings (MHID) in neuropathic 
DFUs (NDFUs) and MHID’s ability to disinfect ulcers [30]. Sixty-three 
type two (II) diabetic patients (n=63) were randomly assigned into two 
groups (Table 3); 32 patients were treated with MHID and 31 patients 
were treated with CD [30]. The study was conducted over a period 
of 16-weeks and patients were administered empirical antibiotic 
monotherapy in patients with severe infections. The majority of the 
MHID-treated group (97%) exhibited complete healing in comparison 
to the CD group (90%). In addition, there was a significant difference in 
the mean duration of healing between the two groups. The NDFUs in the 
MHID-treated group took 27–35 days to heal whereas CD-treated NDFUs 
took 40–46 days to heal completely [30]. Both groups exhibited mixed 
bacterial growth in the wounds, however, 78.13% of MHID-treated 
patients presented with sterile wounds within the 1st week of treatment 
in comparison to 35.5% of CD-treated patients [30]. Evidence from 
this study showed that none of the MHID patients required antibiotic 
treatment while 9 patients in the CD-treated group, did [30].
A controlled clinical trial study conducted by Agarwal et al. (2015) 
compared the efficacy of honey with PVP-I as a dressing material in 
the management of DFUs in 36 patients (Table 3) [31]. All patients 
all presented with non-insulin-dependent DM with Wagner grade-II 
DFUs. The patients were divided into two groups, namely, Group A, the 
honey impregnated dressing group and Group B, the PVP-I dressing 
group [31]. The study was conducted over a period of one (1) year. 
The blood glucose levels of these patients were kept optimum under 
supervision. Streptococcus sp. Staphylococcus sp., Pseudomonas, 
Acinetobacter, E. coli, and polymicrobial infections were isolated from 
the wounds of these patients [31]. At the end of the study, a reduced 
bacterial load was recorded in the wounds of both groups, indicating 
that honey was able to reduce infection. In the honey-treated group, 
wound healing took an average of 14.2 days whereas wounds treated 
with the standard dressing took 15.5 days to heal [31]. All patients in 
the honey Group A experienced reduced pain (pain score of 5.3) during 
treatment in comparison to Group B (pain score of 6.6). the patients 
also presented with reduced oedema. In addition, a reduced amount of 
discharge was recorded with honey-treated wounds [31].
Honey is often used in combination with other dressings to further 
enhance its activities. In a study performed by Hammouri (2004) [32], 
honey/saline dressings were compared to PVP-I/hydrogen peroxide 
dressings (applied in a 3:1 ratio) in the management of DFUs (Table 3). 
The study consisted of two hundred (n=200) patients and ran over a 
period of 5 years. The following parameters namely, healing, hospital 
stay, and cost, were analyzed. The patients were divided equally into 
two groups (n=100) [32]. The study noted that the patients treated 
with the honey dressings had a shorter hospital stay (13 days) in 
comparison to the patients treated with PVP-I (23 days). The authors 
also noted that 10 patients from the PVP-I group failed to respond to 
treatment and were therefore treated with the honey dressings instead. 
Eight (8) of these wounds exhibited dramatic improvement in healing, 
however, the remaining two had to undergo amputation [32]. Bacterial 
culture swabs were taken weekly from the wounds of the patients and it 
was found that 15 of the patients in the honey dressing group exhibited 
clean wounds after just 7 days of treatment [32].
A RCT was conducted by Tsang et al. (2017) [33] to examine the 
effectiveness of nanocrystalline silver (nAg) against MH and CD in 
the healing of severe DFUs in terms of ulcer healing, infection and 
inflammation (Table 3) [33]. The study was conducted over 12 weeks 
with nine observation appointments throughout [33]. Thirty-one 
(n=31) patients were randomized into three groups namely, the nAg 
group (n=11), the MH group (n=10), and the CD group (n=10) [33]. 
The authors recorded that the nAg-treated group exhibited the highest 
wound healing rate of (81.8%, with the MH-treated group exhibiting a 
50% wound healing rate and the CD-treated group with 40% [33]. The 
amount of microbial colonization located in the wounds of the three 
groups decreased over the 12 weeks. The authors noted that the MH 
and nAg-treated groups exhibited a significant decrease in the number 
of microorganisms present in the wound [33]. In the CD-treated 
group, 4 patients experienced severe adverse effects in comparison to 
1 patient in each of the nAg and MH-treated groups, who experienced 
calf swelling and a generalized blister, respectively [33].
Jan et al. (2012) conducted a quasi-experimental study to compare 
conventional pyodine dressings (Group A) to honey dressings (Group B) 
in 100 patients with diabetes and Wagner grade I-VI DFUs (Table 3) [34]. 
The study was conducted over a 1-year period. Patients were divided 
equally between the two groups [34]. The groups were treated with 
the respective dressings daily and blood glucose levels were properly 
monitored in the diabetic patients throughout the study [34]. The 
authors recorded that in 30% of patients in Group A, healed in the first 
2–4 weeks of treatment while 44% healed in weeks 8–10. In Group B, 
60% of patients healed in the first 2–4 weeks of treatment whereas 
6% of patients healed in weeks 8–10, therefore indicating that the 
recovery time was faster in Group B in comparison to Group A [34]. The 
amputation rate was lower in patients in Group B (28%) in comparison 
to patients in Group A (34%) [34]. The authors raised the concern that 
the strong bactericidal effects of pyodine on wound healing may be a 
common explanation for the delay in wound healing, as the preparation 
may have a harmful effect on healing tissue [34].
A study conducted by Ur-Rehman et al. (2013) aimed to compare the 
wound healing properties of honey to PVP-I/saline dressings in Wagner 
grade I and II DFUs (Table 3) [35]. The study was conducted over 
six (6) months and included 60 patients that were randomly assorted 
into two equal numbered groups. The authors measured the percent 
decrease in wound size and analyzed the antimicrobial effects of both 
dressings. The decrease in wound size of the honey treated group 
(80.81±17.27%) was better when compared to the PVP-I treated group 
(54.63±3.42%) [35].
Mukherjee et al. (2018) conducted a study to compare the efficacy of 
honey and PVP-I in different chronic wounds (Table 3) [36]. DFU and PU 
wounds made up 50% in the honey-treated group and 52% in the PVP-I 
dressing group, respectively. The study comprised of 100 patients that 
were equally divided into a honey-treated group (Group A) and a PVP-I 
treated group (Group b) [36]. The authors noted the average pain score 
experienced by patients after 1 month of treatment and then again after 
3 months. The honey treated group experienced a 2.42 point pain score 
at one month, which then reduced to 0.16 at three months [36]. The 
surface area of these wounds also reduced from 1.98 cm2 to 0.27 cm2 after 
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3 months [36]. In comparison to the PVP-I treated group, the average pain 
score at 1-month post-treatment was 2.58 and then 0.76 at 3 months. The 
surface area of these wounds did not reduce as much as those in the honey 
treated group, as they reduced from 2.42 cm2 to 0.51 cm2 [36].
The results of the studies included in this review are summarized below 
(Table 3). 
DISCUSSION
Honey is an ancient remedy that has been used for hundreds of years for 
the treatment of infected wounds and to accelerate wound healing [19]. 
The role of honey as an antiseptic dressing material has been studied by 
several researchers [21-36]. PUs and DFUs present with polymicrobial 
infections were found to delay wound healing and edema, placing a 
patient at risk for serious complications. In addition, these ulcers also 
cause increased pain and discomfort experienced by the patient and 
present with malodor. This review aimed to investigate the efficacy 
and safety of honey as an alternative to standard antiseptic care in the 
treatment of PUs and DFUs in adults.
Chronic wounds are defined by remaining in the inflammatory phase 
of the wound healing process [25]. This delays the ability of a wound to 
heal and progress to the next phase. Honey was shown to exhibit anti-
inflammatory effects which in turn, reduced the wound healing time. This 
can be explained through the dual effect of honey on the inflammatory 
response [25]. Honey suppresses the production of inflammatory cells 
at the wound site, and it stimulates the production of proinflammatory 
cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1β or 
IL-6, involved in the normal wound healing process [25]. Honey was 
found to exhibit its anti-inflammatory and wound-promoting effects by 
accelerating the wound healing rate in comparison to other antiseptics, 
such as PVP-I. These findings were supported by studies conducted by 
Gulati et al. (2014), Zeleníková et al. (2019), Choudhary et al. (2015), 
Jan et al. (2012), and Mukherjee et al. (2018) [21,26,28,34,36]. The 
authors mentioned that faster wound healing was observed in PUs 
and DFUs when dressed with honey [21,26,28,34,36]. In the study 
conducted by Mukherjee et al. (2018), honey-treated chronic wounds 
exhibited significant wound closure and healing (86% of patients) in 
a 3 month period when treated with honey in comparison to PVP-I 
treatment (50% of patients) [36]. Thus, honey had significantly better 
wound healing in comparison to conventional PVP-I [36]. Khadanga 
et al. (2014) noted that honey-treated wounds exhibited a reduction 
in the bacterial load and the size of the PU was significantly reduced in 
these patients [27].
Gulati et al. (2014), Zeleníková et al. (2019), Khadanga et al. (2014), 
Mukherjee et al. (2018), and Choudhary et al. (2015) recorded a 
reduction in the mean/median surface area of honey-treated wounds, 
thus exhibiting honey’s ability to promote wound closure [21,26- 28,36]. 
The increased wound healing may be due to the ability of honey 
to promote fibroblast proliferation, collagen deposition and tissue 
regeneration [23]. These processes are required for wound closure 
and healing. Honey rapidly replaces slough with granulation tissue and 
promotes rapid epithelialization [23] which is achieved by fibroblast 
and epithelial cell growth. These cells grow at the epidermal layer of 
the skin and are involved in wound closure and skin formation [23]. 
The sugary wet environment that honey provides in the wound 
bed improves local nutrition and epithelialization to the skin, thus 
increasing tissue granulation and closure [20,23]. A study by Shukrimi 
et al. (2008) found that DFU wounds granulated well and that the ulcers 
were free of infection at the end of the study, which shows that the 
process of wound healing was more effective [18]. Honey was found 
to promote collagen synthesis and storage due to the presence of nitric 
oxide (NO) in honey [23] which promotes vasodilation, angiogenesis, 
upregulates vascular homeostasis, and promotes tissue healing [21,23].
A study conducted by Gulati et al. (2014) reported that two patients 
had to be removed from the trial owing to the toxic effects associated 
with the use of PVP-I such as skin irritation. The patients treated with 
honey exhibited no adverse effects during treatment [21]. Mukherjee 
et al. (2018) noted that none of the patients experienced adverse effects 
when treated with honey in comparison to PVP-I treated patients [36]. 
These findings support the fact that PVP-I does not satisfy all the criteria 
of an ideal antiseptic agent and is limited in its application because of 
its iodine content [23-26]. Tsang et al. (2017) also recorded that only 
one patient in the MH-treated group for DFU treatment exhibited an 
adverse effect namely, a generalized blister [36].
In several of the studies analyzed, a ‘Wound Score system’ was used 
when analyzing the wound healing rate of PUs and DFUs in response 
to treatment [14]. The system quantifies the severity of the wound 
as “healthy” (7.5 to 10 points), “problematic” (3.5 to 7 points), 
or “unavailing” (0 to 3 points) and provides the basis for wound 
management strategies [14]. In the study conducted by Choudhary et al. 
(2015), the patients treated with honey dressings showed a 20% higher 
wound healing rate in comparison to those treated with betadine [28]. 
Jan et al. (2012) recorded that more than 30% of the patients in the 
honey-treated group presented with wound healing in week 2–4 of 
treatment, in comparison to the pyodine-treated group [34]. More 
patients in the honey-treated group presented with successful healing 
toward the end of the study period in comparison to the pyodine-treated 
group [34]. This is owing to honey’s acidic pH that increases oxygen 
release from hemoglobin and stimulates the activity of macrophages 
and fibroblasts, which are involved in tissue regeneration [22,23]. 
Honey’s ability to improve wound healing was also recorded in the 
study by Zeleníková et al. (2019) which concluded that the application 
of honey dressings in non-healing wounds resulted in faster healing 
and wound size reduction [26]. Among the patients receiving honey 
dressings, 80% presented with completely healed wounds within 
3 months in comparison to 30% of the control group [26]. Honey’s 
antioxidant and anti-inflammatory effects were found to accelerate the 
wound healing process. Flavonoids are phytochemicals found within 
medical grade honey that inhibit the formation of superoxide free 
radicals which protects infected tissues from further damage [23].
Evidence from studies conducted by Khadanga et al. (2014), Shukrimi 
et al. (2008), and Kamaratos et al. (2014) showed a reduction in 
bacterial growth or colonization within the wound bed in the honey-
treated groups [27,29,30]. Honey-impregnated wound dressings 
seem to disinfect wounds and provide a lower bacterial count to 
ensure an optimum environment for healing. These studies confirmed 
honey’s ability to eradicate infection [27,29,30]. Honey contains low 
concentrations of H2O2 that promotes fibroblast proliferation and 
collagen deposition, which indirectly removes bacteria in the wound 
bed [23]. Honey stimulates angiogenesis for proliferating cells thus 
providing blood, oxygen and nutrients to neutrophils, and other cells, 
involved in the inflammatory and wound healing process [23]. Honey’s 
high sugar content draws fluid out of the wound bed by osmosis 
which dehydrates bacteria and damages their cell walls, leading to cell 
death [22,23]. Its acidic pH inhibits the growth of bacteria within the 
wound as bacteria require a more alkaline environment to survive. 
Honey’s thick consistency makes it a successful barrier from the 
external environment and foreign material [22,23]. It also prevents 
cross-infection as it creates a moist antibacterial environment that 
rapidly eliminates bacteria in the wound [23]. All of these mechanisms 
result in the reduced incidence of infection and the eradication of 
bacteria in the wound bed [23-26]. A study conducted by Kamaratos 
et al. (2014) showed that no additional antibiotic treatment was needed 
when treating patients with MH dressings as they recorded a rapid 
clearance of the bacterial load in DFUs with the use of honey alone [30].
Amputations are often necessary for diabetic patients that present with 
DFUs, due to restricted blood flow to the lower limb and uncontrollable 
bacterial infections. Hammouri (2004) and Jan et al. (2012) both 
mentioned that the amputation rate in honey-treated DFU patients 
in the respective studies, was significantly lower than those treated 
with CD [32,34]. This supports the theory that honey can stimulate 
angiogenesis in the wounded area and increase blood flow, thus 
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promoting wound healing [19]. In addition, honey’s antibacterial 
properties eradicate microbial colonization in the wound bed, therefore 
preventing severe infection that may lead to amputation [23-26].
PUs and DFUs present with slow healing owing to infection, ischemia 
and neuropathy [14]. Shukrimi et al. (2008), Choudhary et al. (2015), 
and Agarwal et al. (2015) concluded that honey aids in reducing swelling 
and water retention in the wound bed and aids in the reduction of 
wound discharge [28,29,31]. This is owing to honey’s ability to reduce 
oedema as its high osmolarity allows it to absorb water [22-24] which 
improves lymphatic drainage and blood circulation, thereby improving 
wound healing [22,23]. Its high osmotic pressure content enables it to 
be successful at wound debridement as it draws fluid out of the wound 
bed, thus, reducing the amount of exudate present [22-24]. This further 
relieves pressure from the wound bed and allows for proinflammatory 
cells to be recruited efficiently to the wound site thus aiding in the 
process of healing.
Gulati et al. (2014), Zeleníková et al. (2019), Shukrimi et al. (2008), 
Agarwal et al. (2015), and Mukherjee et al. (2018) mentioned that dressing 
changes with honey were less painful for patients [21,26,29,31,36]. 
This can be attributed to the ability of honey to maintain the moisture 
level of wounds without adhesion to the surface and increasing blood 
and nutrient supply to the open wound [18]. As a result, treatment of 
PUs and DFUs with honey will provide more comfort to the patient and 
will make the healing process easier and efficient [18]. Mukherjee et al. 
(2018) noted that patients treated with honey dressings experienced 
significantly less pain (reduced pain score by 2.26 points) over a period 
of 3 months in comparison to patients treated with PVP-I dressings 
(reduced pain score by 1.82 points) [36].
Honey was found to reduce the pungent smell associated with PUs and 
DFUs, in studies conducted by Shukrimi et al. (2008) and Zeleníková 
et al. (2019) [26,29]. This is achieved by honey’s ability to neutralise 
odor-inducing compounds (sulphur dioxide and NO) released by 
bacteria within the wound bed as well as honey’s debriding activity 
and its ability to remove dead and necrotic tissue [23-25]. In addition, 
honey contains glucose which provides an alternative nutrient source 
for bacteria within the wound bed which results in the production 
of lactic acid as a waste product rather than sulfur-containing 
compounds [22,23].
Kamaratos et al. (2014), Khadanga et al. (2014), and Shukrimi et al. 
(2008) all highlighted that there were significant economic benefits in 
using honey in DFU wound care [27,29,30]. Hammouri (2004) noted 
that the introduction of honey dressings as a method of treating DFUs, 
reduced the cost of treatment by 50% [32]. DFUs require long periods 
to heal and are associated with financial implications and long-term 
hospital stays. As a result, the overall cost associated with the use of 
wound dressings containing honey may be more cost-effective and 
economical in comparison to standard treatment [29].
The authors in the abovementioned studies also noted that honey 
dressings were easier to apply, with less damage to granulating 
tissue, compared to those of conventional treatment [32]. The ease 
of its application and its easy availability makes it a suitable first-aid 
treatment for PUs and DFUs and can be managed by novice clinicians.
LIMITATIONS
Additional research will need to be conducted to support the findings 
in this review. The articles included in this study presented with limited 
population sizes that could give rise to bias. Several of the authors did 
not record results periodically, which may result in inaccuracies in the 
results. Several of the studies were conducted over short time periods 
or the study failed to mention the length of treatment, which brings into 
question whether honey significantly accelerates the wound healing 
process in comparison to standard antiseptic care. Mixed etiologies of 
wounds were included in several studies. This makes treatment difficult 
as different wounds take different time periods to heal; treatment 
options may differ and the mixing wounds in this way could have an 
impact on the validity of the analysis.
RECOMMENDATIONS
More randomized studies on larger population sizes and stratifying 
results with wounds of the same etiology and heterogeneity, need to be 
carried out. Studies with pre-specified outcome measures and methods, 
need to be compiled and carried out over appropriate timeframes to 
confirm the advantages of honey in the treatment of PUs and DFUs. 
Chronic wounds can take up to 3 months to heal; therefore, a treatment 
period of 3 months or longer is recommended. This will provide more 
conclusive evidence which can be applied to the general population.
CONCLUSION
Quality research on the clinical role of honey in the treatment of PUs 
and DFUs is extremely limited and is compounded by the complexity 
of wound care and the recruitment of a large number of the patients 
with identical wound etiologies. The relevant studies and trials that 
were found did, however, support the use of honey as an effective 
and safe alternative to antiseptics in the treatment of PUs and DFUs. 
Honey was found to be effective in treating these chronic wounds as 
it exhibited antimicrobial, antioxidant, and anti-inflammatory effects. 
It was found to promote epithelialization and wound-debriding effects 
as well as reducing the pain experienced by the patient. The foul-
odor associated with chronic PUs was reduced when treated with 
the medical grade honey. Honey dressings were found to be highly 
effective in the successful healing of chronic ulcers when compared to 
standard antiseptic care, especially in the trials that analyzed PVP-I. 
If the appropriate wound dressings are used in the patients with PUs 
and DFUs, their quality of life can be greatly improved because of a 
decrease in pain and discomfort, while shorter hospital visits will have 
a positive effect on the financial aspect thereof. As current literature 
on this topic is limited, further research is warranted. This review can 
serve as a foundation for future studies to better understand the safety 
and efficacy of honey to reduce the bacterial burden in the wound bed 
of PUs and DFUs as well as its wound healing effects in comparison to 
standard antiseptics.
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